Feed BAX
BA

Baxter International BAX NYSE · Healthcare · United States

$25.39 +0.00% +$0.00

Summary

33 / 100 · Bulios Score

What speaks for it

  • The price moves less than the market (beta 0.67).

What to watch

  • The company made a loss over the last 12 months.
  • Operating profit does not even cover the interest on its debt.
  • It cut its dividend by 50% last year.
  • The share price is above the Bulios Fair Price.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Price

Is it expensive?

Looks expensive
Bulios Fair Price
Overvalued Price today $25.39

By our assumptions the business is worth less than its shares cost today.

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

The company made a loss over the last 12 months, so there is no profit to set the price against.

Valuation in detail

Is it growing?

It is shrinking

Revenue (USD)

Diluted EPS (USD)

  • Analyst estimate

Revenue fell by 0.7% a year over 5 years. Over the last 3 years it grew by 3.8% a year. For the next fiscal year analysts expect revenue to grow by 4.3%.

Growth in detail

Does it make money?

Poorly

Over the last 12 months it made a loss of $723.0M.

Profitability in detail

Is it financially healthy?

Debt is a burden

Repaying all its debt would take 8.8 years of free cash flow. Its debt is larger than its cash.

Financial health in detail

Does it pay a dividend?

Small, at risk
Yield
0.16%

You receive $0.04 per share a year. The payout is more than the company can comfortably cover.

Dividends in detail

What do analysts expect?

Neutral

Today's price within the analysts' price targets

The average target of $23.6 is 7.1% below today's price. 39% of the analysts recommend buying.

Analysts in detail

What does it earn on?

Fiscal year 2025

By product

By region

Medical Products And Therapies brings in 49% of revenue.

Segments in detail

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy